| abstract |
Humanized, murine or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with optimized Koff values, which interfere with human CD47-SIRPĪ± interaction and find use in various therapeutic, prophylactic or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical preparations comprising one or more of humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines producing these monoclonal antibodies. Amino acid and nucleotide sequences of antibodies are also provided. |